Spots Global Cancer Trial Database for A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
Official Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Study ID: NCT02898077
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
First hospital affiliated to Zhengzhou University, Zhengzhou, Henan, China
Wu Han Tongji Hospital, Wuhan City, Hubei, China
Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
Nan Jing No. 81 Hospital, Nan Jing, Jiang Su, China
Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Tang Du Hospital, The Second Teaching Hospital of FMMU, Xi'an, Shanxi, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Beijing Cancer Hospital, Beijing, , China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, , China
Hospital Umum Sarawak, Kuching, Sarawak, Malaysia
Advanced Medical & Dental Institute HUSM, Kepala Batas, Pulau Pinang, , Malaysia
Hospital Kuala Lumpur, Kuala Lumpur, , Malaysia
University Malaya Medical Centre, Kuala Lumpur, , Malaysia
National Cancer Institute, Wilayah Persekutuan, , Malaysia
Cebu Doctors Hospital, Cebu City, Cebu, Philippines
Dr. Pablo O. Torre Memorial Hospital, Bacolod, , Philippines
De La Salle Health Sciences Institute, Cavite City, , Philippines
Rajavithi Hospital, Bangkok, Ratchathewi District, Thailand
King Chulalongkorn Memoiral Hospsital, Bangkok, , Thailand
Police General Hospital, Bangkok, , Thailand
Khon Kaen Hospital, Muang, Khon Kaen, , Thailand
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
